Medical Director, Virginia G. Piper Cancer Genetic Risk Assessment Center President, OncoGyne, PC

Obstetrics & Gynecology

Mike Janicek works in the field of Obstetrics & Gynecology. He went to medical school at Harvard Medical School. Harvard Medical School is one of the top medical schools in the US. Harvard Medical School is ranked 1/12 in Research/PrimaryCare. He received awards:"Regional Top Doctor", "Career Development Award", "Unrestricted Basic Science Research Grants", "Best Fellow Paper Award (co-winner)", "Basic Science Research Award", "Gynecology and Obstetrics (APGO)/Parke-Davis Scholar", "Best Fellow Paper Award.", "Assembly Prize", "David Mason Little Prize", "Super Doctor", "Development of Human CTLs Targeting Cervical Carcinoma", "Co-PI, Imiquimod (Aldara) as CTL-potentiator in vitro", "Most Compassionate Doctor" and "Fellow (FACOG)". Dr. Mike F. Janicek is a published physician. He published 17 publications, including: 'Close vaginal margins as a prognostic factor after radical hysterectomy.' Dr. Mike F. Janicek accepts Medicare payments and is registered with Medicare.gov.

Publications

---

• Phase I trial of intraperitoneal pemetrexed, cisplatin, and paclitaxel in optimally debulked ovarian Cancer.
• Phase III trial of induction gemcitabine or paclitaxel plus carboplatin followed by paclitaxel consolidation in ovarian Cancer.
• Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in res...
• Pilot study of the prospective identification of changes in cognitive function during chemotherapy treatment for advanced ovarian Cancer.
• Tumor angiogenesis as a prognostic factor in ovarian Carcinoma: quantification of endothelial immunoreactivity by image analysis.
• Ovarian Carcinoma. A review of the significance of familial risk factors and the role of prophylactic oophorectomy in cancer prevention.
• Invasive endometrial Cancer in uteri resected for atypical endometrial hyperplasia.
• In vitro antigene therapy targeting HPV-16 E6 and E7 in cervical Carcinoma.
• Combination anti-gene therapy targeting c-myc and p53 in ovarian Cancer cell lines.
• p53 interference and growth inhibition in p53-mutant and overexpressing endometrial Cancer cell lines.
• Generation of tumor-specific cytotoxic T lymphocytes by stimulation with HPV type 16 E7 peptide-pulsed dendritic cells: an approach to immunotherapy of Cervical cancer.
• Significance of intraperitoneal cytology in patients undergoing radical hysterectomy.
• Close Vaginal margins as a prognostic factor after radical hysterectomy.
• Use of lonidamine to potentiate the effect of cisplatin and carboplatin on platinum resistant human ovarian Cancer cells.
• Early restaging gallium scans predict outcome in poor-prognosis patients with aggressive non-Hodgkin's lymphoma treated with high-dose CHOP chemotherapy.
• High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: a dose-finding pilot study.

Schools

---

• Harvard Medical School

• Johns Hopkins Hospital

• Sylvester Cancer CenterJackson Memorial Hospital University Of Miami

Procedures Preformed

---

• Colpopexy
• Colposcopy
• Destruction or Excision of Lesion of Cervix (incl. LEEP)
• Destruction or Excision of Vaginal Lesions
• View All

Conditions Treated

---

• Asymptomatic Post-Menopausal Status
• Carcinoma in Situ
• Cervical Cancer
• Cervical Polyps
• View All

Doctors Specialties

---

• Gynecologic Oncology
• Obstetrics
• Gynecology

Accepted Insurances

---

Awards

---

• Regional Top Doctor
• Career Development Award
• Unrestricted Basic Science Research Grants
• Best Fellow Paper Award (co-winner)
• Basic Science Research Award
• Gynecology and Obstetrics (APGO)/Parke-Davis Scholar
• Best Fellow Paper Award.
• Assembly Prize
• David Mason Little Prize
• Super Doctor
• Development of Human CTLs Targeting Cervical Carcinoma
• Co-PI, Imiquimod (Aldara) as CTL-potentiator in vitro
• Most Compassionate Doctor
• Fellow (FACOG)

Education

---

• Jackson Memorial Hospital - Jackson Health System
• Johns Hopkins University
• Harvard Medical School
• Harvard College

Drug Facts

---

NPI NUMBER		1639171754
NPPES Provider LastName		JANICEK
NPPES Provider FirstName		MIKE
NPPES Provider ZIPCode		852584560
NPPES Provider State		AZ
Specialty Description		Gynecological/Oncology
Total Claim Count		453.0
Distinct Opioid Count		3.0
Opioid Claim Count		79.0
Percent Opioid Claims		17.44

Helpful Reviews

---

Give Anonymous Review

Medicare Facts

---

National Provider Identifier [NPI]	1639171754
Last Name Of The Provider	JANICEK
First Name Of The Provider	MIKE
View All

Similar Doctors

---

	Dr. Julie A. Castilla, MD This Doctor is OpenDoctor Recommended.
	Dr. Charles A. Bollmann, MD This Doctor is OpenDoctor Recommended.
	Dr. John H. Malfetano, MD This Doctor is OpenDoctor Recommended.
	Dr. Burt G. Webb, MD This Doctor is OpenDoctor Recommended.
	Dr. Nora Bassiouni, MD This Doctor is OpenDoctor Recommended.

---

Doctor Directory | TOS | twitter | FB | Angel | blog